Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

ImmuCell Corporation ICCC

Healthcare  —  Biotechnology
9.93 (0.04) (0.40%) as of 25 Sep
Market cap
$90.6M
P/E
117×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

ImmuCell Corporation (ICCC) Business Profile

Updated before January 2025

Company Overview

ImmuCell Corporation (ICCC) is a biotechnology company focused on the development, production, and commercialization of products that improve animal health and productivity in the dairy and beef industries. Founded in 1982 and headquartered in Portland, Maine, ImmuCell has carved a niche in the animal health sector by addressing critical challenges faced by livestock producers. The company’s mission is to provide scientifically advanced solutions that enhance the health and well-being of animals, ultimately benefiting the agricultural economy.

ImmuCell’s leadership team is composed of experienced professionals with deep expertise in biotechnology, veterinary medicine, and business management. Michael F. Brigham serves as the President and Chief Executive Officer, bringing decades of experience in corporate leadership and strategic planning. The company’s board of directors and executive team work collaboratively to drive innovation and maintain a strong market presence.

Core Business Segments

ImmuCell operates primarily in the animal health sector, with a focus on developing products that address the needs of dairy and beef producers. The company’s core business segments include:

1. First Defense® Product Line

  • First Defense® Bolus: A leading product designed to prevent scours (diarrhea) in newborn calves caused by E. coli and coronavirus. This product is a colostrum-derived antibody supplement that provides passive immunity to calves.
  • First Defense® Tri-Shield: An advanced version of the First Defense® product, offering protection against three pathogens: E. coli, coronavirus, and rotavirus.

2. Re-Tain®

  • Re-Tain® is an innovative product aimed at treating subclinical mastitis in lactating dairy cows without requiring milk discard. This product is currently under regulatory review and is expected to be a game-changer in the dairy industry.

3. Nisin-Based Products

  • ImmuCell is exploring the use of nisin, a natural antimicrobial peptide, for various applications in animal health. Nisin has shown promise in addressing bacterial infections and improving overall herd health.

4. Diagnostic and Research Services

  • The company also offers diagnostic and research services to support livestock producers and veterinarians in managing herd health effectively.

Business Model

ImmuCell’s business model revolves around the integration of research, product development, manufacturing, and commercialization. The company invests heavily in research and development (R&D) to create innovative solutions that address unmet needs in the animal health industry. By maintaining in-house manufacturing capabilities, ImmuCell ensures high-quality production standards and cost efficiency.

Revenue generation primarily comes from the sale of its First Defense® product line, which has established a strong market presence. The company also anticipates significant revenue growth from the commercialization of Re-Tain® once it receives regulatory approval. ImmuCell’s direct sales efforts are complemented by partnerships with distributors and veterinary networks, ensuring broad market reach.

Strategic Direction

ImmuCell is committed to expanding its product portfolio and market presence. Key strategic initiatives include:

  • Commercialization of Re-Tain®: The company is focused on obtaining regulatory approval for Re-Tain® and launching it in the market. This product has the potential to revolutionize mastitis treatment in dairy cows.
  • Geographic Expansion: ImmuCell aims to increase its international footprint by entering new markets and strengthening its presence in existing ones.
  • Sustainability Goals: The company is dedicated to promoting sustainable agricultural practices by providing products that improve animal health and reduce the need for antibiotics.
  • Innovation Pipeline: ImmuCell continues to invest in R&D to develop new products and technologies that address emerging challenges in the livestock industry.

Competitive Landscape

ImmuCell operates in a competitive market, facing competition from both large multinational corporations and smaller specialized firms. Key competitors include:

  • Zoetis Inc.: A global leader in animal health, offering a wide range of vaccines, diagnostics, and pharmaceuticals.
  • Elanco Animal Health: Another major player in the industry, providing innovative solutions for livestock and companion animals.
  • Boehringer Ingelheim Animal Health: Known for its extensive portfolio of animal health products, including vaccines and therapeutics.
  • Smaller Niche Players: Companies like Epitopix and Agrilabs also compete in specific segments of the animal health market.

ImmuCell differentiates itself through its focus on colostrum-derived products and its commitment to addressing specific challenges faced by dairy and beef producers.

Risk Factors

ImmuCell faces several risks that could impact its business operations and financial performance:

  • Regulatory Approval Delays: The commercialization of Re-Tain® is contingent on obtaining regulatory approval, and any delays could affect revenue growth.
  • Market Dependence: The company relies heavily on the success of its First Defense® product line, making it vulnerable to market fluctuations.
  • Supply Chain Disruptions: Disruptions in the supply chain, including raw material shortages or manufacturing issues, could impact product availability.
  • Competition: Intense competition from larger players with greater resources poses a challenge to ImmuCell’s market share.
  • Economic Factors: Changes in the agricultural economy, such as fluctuations in milk and beef prices, could affect demand for the company’s products.

Recent Developments

ImmuCell has made significant strides in recent years, including:

  • Advancements in Re-Tain® Development: The company has completed key milestones in the regulatory approval process for Re-Tain® and is preparing for its commercial launch.
  • Expansion of Manufacturing Capacity: ImmuCell has invested in expanding its production facilities to meet growing demand for its products.
  • Partnerships and Collaborations: The company has strengthened its distribution network through strategic partnerships with veterinary organizations and distributors.
  • Response to Global Challenges: ImmuCell has adapted to challenges posed by the COVID-19 pandemic and supply chain disruptions, ensuring business continuity and product availability.

Investment Considerations

Investors considering ImmuCell as a potential investment should weigh the following factors:

Strengths:

  • Established market presence with the First Defense® product line.
  • Strong focus on innovation and R&D.
  • Potential for significant revenue growth with the launch of Re-Tain®.
  • Commitment to sustainability and addressing industry challenges.

Risks:

  • Dependence on a limited product portfolio.
  • Regulatory and competitive pressures.
  • Vulnerability to economic and market fluctuations.

Conclusion

ImmuCell Corporation is a pioneering company in the animal health sector, offering innovative solutions that address critical challenges faced by dairy and beef producers. With a strong product portfolio, a commitment to sustainability, and a focus on innovation, ImmuCell is well-positioned for future growth. However, investors should carefully consider the risks associated with regulatory approvals and market dependence. Overall, ImmuCell’s strategic initiatives and dedication to improving animal health make it a compelling player in the biotechnology industry.